Santhera Pharmaceuticals, AOTI, Poolbeg Pharma, Solvonis Therapeutics, IBT

By Proactive Investors / May 01, 2026 / www.youtube.com / Article Link

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) nearly doubled revenues to CHF 77.2 million in 2025, driven by ...

Recent News

Big Gold still struggling overall in 2026

September 28, 2026 / www.canadianminingreport.com

Gold stocks down on metal price pullback

September 28, 2026 / www.canadianminingreport.com

Mining sector far outpaces tech over past three years

September 21, 2026 / www.canadianminingreport.com

Gold stocks down with GDXJ outperforming on rebalancing

September 21, 2026 / www.canadianminingreport.com

Copper slides as US apparently wavering on tariff hikes

September 14, 2026 / www.canadianminingreport.com

See all >